Aytu BioPharma Reports Significant Q3 Revenue Decline and Net Loss Amidst EXXUA Launch

summarizeSummary

Aytu BioPharma announced a sharp drop in Q3 revenue and a significant net loss, driven by a strategic pivot to its new EXXUA drug and declines in its established product lines.

check_boxKey Events

• Significant Revenue Decline

  Net revenue fell 32.97% year-over-year to $12.4 million in Q3 fiscal 2026 from $18.5 million in Q3 fiscal 2025.

• Swing to Net Loss

  The company reported a net loss of $5.6 million, a significant deterioration from a net income of $4.0 million in the prior year period.

• Negative Adjusted EBITDA

  Adjusted EBITDA turned negative at $(2.8) million, down from $3.9 million in Q3 fiscal 2025, reflecting EXXUA launch investments.

• EXXUA Launch Traction

  The new major depressive disorder drug, EXXUA, generated $2.4 million in net revenue during its partial launch quarter, showing early adoption.

auto_awesomeAnalysis

Aytu BioPharma reported a substantial decline in fiscal Q3 2026 net revenue and swung to a significant net loss, primarily due to a strategic shift in sales focus to the new EXXUA product and generic competition impacting its legacy ADHD and Pediatric portfolios. While EXXUA showed initial traction with $2.4 million in revenue, it was not enough to offset the broader revenue contraction and increased launch investments, leading to a negative adjusted EBITDA. This financial deterioration is significant for a company of its market capitalization.